SAN JUAN CAPISTRANO, Calif.--(EON: Enhanced Online News)--Allegro Ophthalmics, LLC, a company dedicated to establishing Integrin Peptide Therapy as the next-generation pharmaceutical category for the treatment of vascular eye diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved the company’s Investigational New Drug (IND) application to begin two Phase II clinical studies of ALG-1001. These Phase II clinical trials will be conducted in patients with wet age-related macular degeneration (wet AMD) and in patients with symptomatic vitreomacular traction (VMT).
“In just over three years, we’ve rapidly and methodically gone from compound discovery to Phase II clinical trials. We are optimistic that this drug will continue to show efficacy and provide meaningful therapeutic benefit to patients with vascular eye diseases such as wet AMD and VMT.”
“We are extremely pleased with the FDA’s approval, which validates our preclinical data, multiple Phase I study results, and Phase II clinical study design,” said Vicken Karageozian, M.D., Co-Founder and Chief Technical Officer, Allegro Ophthalmics. “In just over three years, we’ve rapidly and methodically gone from compound discovery to Phase II clinical trials. We are optimistic that this drug will continue to show efficacy and provide meaningful therapeutic benefit to patients with vascular eye diseases such as wet AMD and VMT.”
These Phase II studies will be the fifth and sixth studies of ALG-1001. Completed already are two Phase I studies – one monotherapy study in each of diabetic macular edema (DME) and wet AMD. Additionally, two Phase Ib/IIa studies are in progress, with one being a combination study in DME. To date, all data from human studies, as well as studies in animals, show Integrin Peptide Therapy to be safe, well-tolerated and efficacious, including the fact that the benefit of monotherapy is holding at least three months off-treatment in both wet AMD and DME patients.
About Integrin Peptide Therapy and its Role in Treating Vascular Eye Diseases
ALG-1001 is a first in class Integrin Peptide Therapy targeting integrins, which play a key role in cell signaling and regulating cellular shape, motility, and the cell cycle. ALG-1001 approaches multiple indications by collectively turning off the production of aberrant blood vessels, reducing the leakage of aberrant blood vessels, and inhibiting the growth of aberrant blood vessels.
To learn more about Allegro Ophthalmics and Integrin Peptide Therapy, please visit www.allegroeye.com or contact Marc Kirshbaum, Chief Operating Officer, Allegro Ophthalmics, at firstname.lastname@example.org.
About Allegro Ophthalmics, LLC
With more than 100 years of combined experience in vision science and medicine, the leadership team at Allegro Ophthalmics, LLC is establishing Integrin Peptide Therapy as the next-generation pharmaceutical category for the treatment of wet age-related macular degeneration, diabetic retinopathy and diabetic macular edema, which together affect nearly six million Americans. Allegro Ophthalmics seeks to prevent vision loss and combat blindness, potentially offering millions an improved quality of life sustained by self-sufficient, functional vision. For more information, visit www.allegroeye.com.